Blog

Jun 27, 2025, 07:02

Elsevier Oncology – Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC

Elsevier Oncology posted on LinkedIn:

“From the Journal of Thoracic Oncology’s Editor’s Choice collection: compelling phase 1 data in NSCLC therapy.

Han B et al. present findings on Asandeutertinib’s safety, pharmacokinetics, and efficacy in advanced EGFR-mutated NSCLC.”

Title: Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC: A Phase 1 Dose-Escalation and Dose-Expansion Study

Authors: Baohui Han, Jie Liu, Lin Wu, Yanqiu Zhao, Wei Zhang, Bolin Chen, Jianbo He, Jianhua Shi, Yanqing Liu, Zhe Zhang, Xiugui Chen, Yusheng Wu

Read The Full Article.

Elsevier Oncology - Safety, Pharmacokinetics, and Efficacy of Asandeutertinib in Advanced EGFR-mutated NSCLC

More posts featuring Lung Cancer.

Baohui Han Bolin Chen Elsevier Oncology Jianbo He Jianhua Shi Jie Liu Journal of Thoracic Oncology Lin Wu Lung cancer NSCLC Wei Zhang Xiugui Chen Yanqing Liu Yanqiu Zhao Yusheng Wu Zhe Zhang

James Whale Dies at 74: The Radio Icon’s Long Fight Against Kidney Cancer

Top GU Immunotherapy Trials to Watch at ESMO 2025

Julie Gralow Received the 2025 NCG Lifetime Achievement Award in Oncology

FDA Fast Track for CLD-201: Stem Cell–Based Oncolytic Virus for Soft Tissue Sarcoma

Jessica Posada Was Named Inaugural Recipient of the Debbie’s Dream Early Career Investigator Award